VitMode

PDE5 Inhibitors (Viagra, Cialis): How They Really Work and Who They're Safe For

Sildenafil (Viagra) and tadalafil (Cialis) are today's best-studied drugs for erectile dysfunction anywhere in the world — sildenafil transformed sexual medicine back in 1998, and data from tens of thousands of patients have accumulated since. Yet plenty of oversimplifications still circulate about both drugs: from the belief that they work like an aphrodisiac, to underestimating one absolutely dangerous drug interaction. We check what the pivotal trials actually showed, how the two drugs differ, and what the real risks of using them are.

PZdr Piotr ZielińskiSeptember 4, 202614 min read
Table of contents

One mechanism, two drugs, a very different story than a "potency pill"

Sildenafil (Viagra), approved by the FDA in March 1998, was the first effective oral drug for erectile dysfunction and literally launched a new category of pharmacotherapy. A few years later it was joined by tadalafil (Cialis), differing mainly in duration of action. Both drugs belong to the phosphodiesterase type 5 (PDE5) inhibitor class, and despite being widely treated as a "potency pill," they don't act like an aphrodisiac — they don't increase sexual desire or trigger an erection on their own.

The mechanism is strictly physiological: during natural sexual arousal, nitric oxide is released in the penile corpus cavernosum, activating the enzyme guanylate cyclase and raising levels of cGMP — a molecule that relaxes vascular smooth muscle and allows blood inflow. The PDE5 enzyme naturally breaks down cGMP, ending the erection. PDE5 inhibitors block this enzyme, so cGMP persists longer and an erection becomes easier to achieve and maintain — but only in response to actual sexual arousal, not automatically after taking a pill.

This is not a libido-boosting drug

PDE5 inhibitors act at the vascular level, not on hormonal or neurological drive. If the main problem is low sexual desire rather than a mechanical difficulty achieving an erection, it's worth first considering hormonal diagnostics — described in more detail in our entry on diagnosing hypogonadism — instead of reaching for a PDE5 inhibitor hoping it will improve interest in sex.

What the sildenafil pivotal trial showed

Oral Sildenafil in the Treatment of Erectile Dysfunction

Strong evidence

Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (Sildenafil Study Group) · New England Journal of Medicine · 1998

Two randomized pivotal trials. In the first, 532 men received sildenafil (25, 50, or 100 mg) or placebo for 24 weeks. In the second, a 12-week trial with flexible dose titration up to 100 mg, 329 men participated, with a 32-week extension for 225 of them. At the 100 mg dose, erectile function scores improved 100% relative to baseline. During the final four weeks of the dose-escalation phase, successful intercourse was reported in 69% of attempts in the sildenafil group versus 22% on placebo. The most common adverse effects — headache, facial flushing, dyspepsia — occurred in 6–18% of participants.

View study

Even more than twenty-five years on, this trial remains the foundation of sildenafil's approval — and one of the most frequently cited studies in all of urology. A gap of 69% versus 22% in successful attempts is a large effect size rarely seen in chronic-disease pharmacotherapy — most drugs used daily in medicine produce differences of a few percentage points versus placebo, not tens of points.

It's worth noting, though, that the trial covered a mixed population of men with erectile dysfunction of varying severity and cause (vascular, diabetic, psychogenic, post-surgical). Effectiveness in any given case depends heavily on the underlying cause — men with severe nerve damage after prostate surgery tend to respond much less well than this averaged trial population.

Tadalafil: a longer window of action, a different patient profile

The key difference between sildenafil and tadalafil is pharmacokinetics. Sildenafil typically acts for 4–6 hours and works best taken on an empty stomach, 30–60 minutes before planned activity — food, especially fatty food, significantly delays its absorption. Tadalafil has a much longer half-life and acts for up to 36 hours, earning it the nickname "the weekend pill," and also allowing approval of a once-daily low-dose regimen (2.5–5 mg) independent of planned sexual activity.

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies

Strong evidence

Porst H, Gacci M, Büttner H, Henneges C, Boess F · European Urology · 2014

A pooled analysis of six randomized, placebo-controlled trials covered 1913 men assigned to placebo or tadalafil 2.5 mg or 5 mg once daily for 12 weeks. Both doses significantly improved erectile function scores versus placebo. Patients with hypertension, heart disease, or elevated cholesterol achieved clinically meaningful improvement at either dose, while obese patients, smokers, and those with a psychogenic component required the higher 5 mg dose. Among patients with severe erectile dysfunction, 44.5% treated with the 5 mg dose reached a defined improvement threshold, versus 11.6% on placebo.

View study

Effectiveness depends on who's taking the drug, not just the dose

Strong evidence

This trial is especially useful clinically because it shows more than an averaged effect — it breaks efficacy down by patient subgroup. The same dose performs differently depending on coexisting cardiovascular and metabolic risk factors, which has direct practical relevance for dose selection, not just for interpreting the pooled result.

The interaction you must never forget: nitrates

Absolute contraindication: nitrates and nitric oxide donors

Taking PDE5 inhibitors together with nitrates (e.g., nitroglycerin used for angina) or nitric oxide donors is absolutely contraindicated and can cause a sudden, life-threatening drop in blood pressure. Both act on the same nitric oxide–cGMP pathway, and combining them compounds the vasodilatory effect in an uncontrolled way. This also applies to some over-the-counter "potency boosters," which have repeatedly been found to contain undeclared sildenafil combined with other substances — a man taking nitrates for coronary artery disease should never take a PDE5 inhibitor without explicit clearance from a cardiologist.

Caution is also warranted with alpha-blockers, often prescribed for enlarged prostate — combining the two can worsen blood pressure drops, though less severely than with nitrates. Doctors usually recommend spacing out the timing of the two drugs or choosing a lower PDE5 dose when an alpha-blocker is also being used.

A rare but real risk: sudden vision loss (NAION)

A rare but serious complication reported in connection with PDE5 inhibitor use is non-arteritic anterior ischemic optic neuropathy (NAION) — sudden, usually one-sided vision loss caused by inadequate blood flow to the optic nerve. Evidence for a direct causal link is mixed, but one of the better-designed studies sheds some light on it.

Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure

Moderate evidence

Flahavan EM, Li H, Gupte-Singh K, Rizk RT, Ruff DD, Francis JL, Kinchen KS · Urology · 2017

A case-crossover study enrolled 279 men with confirmed NAION from 41 US ophthalmology sites (2010–2015), analyzing their history of PDE5 inhibitor exposure. Among participants, 22 had intermittent PDE5 inhibitor exposure within 30 days before symptom onset. The analysis found a rate ratio of 2.27 (95% CI: 0.99–5.20) for the 30-day window and 3.52 (95% CI: 1.59–7.79) for the 12-month window, suggesting an elevated risk of NAION associated with PDE5 inhibitor use. A matched-interval analysis found no significant association. The authors emphasized that patients and clinicians should continue weighing the benefits and risks of PDE5 inhibitor use, including the potential NAION risk.

View study

A worrying signal, but not conclusively confirmed

Moderate evidence

The confidence interval for the 30-day window crosses 1 (0.99–5.20), meaning the result sits right at the edge of statistical significance. For the 12-month window the association was significant, but other, larger meta-analyses have produced mixed results — one found no elevated risk at all (OR 1.16; 95% CI 0.89–1.52). Most reported NAION cases in PDE5 users already had other risk factors: a small cup-to-disc ratio, age over 50, diabetes, hypertension, coronary artery disease, dyslipidemia, and smoking. NAION remains a very rare event, but any sudden vision loss while using a PDE5 inhibitor warrants immediate ophthalmologic evaluation and discontinuation of the drug.

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

Myths worth breaking down

Myth

Viagra and Cialis act like an aphrodisiac — they increase the urge for sex and automatically trigger an erection once taken.

Fact

PDE5 inhibitors don't increase libido or trigger an erection without actual physical or psychological sexual arousal — they only facilitate the vascular mechanism that still has to be switched on naturally. A man with no sexual stimulus at all won't get an erection just because he took a pill.

A second common myth is that the two drugs are essentially interchangeable — in practice, choosing between sildenafil and tadalafil isn't a matter of "better versus worse," but of matching the drug to lifestyle and coexisting conditions, which the comparison table below covers in more detail.

Before you reach for a PDE5 inhibitor — what to check first

Practical steps before starting PDE5 therapy

  • Erectile dysfunction, especially sudden-onset and in younger men, is worth diagnosing before treating symptomatically — it can be an early sign of cardiovascular disease, diabetes, or low testosterone
  • Men with coronary artery disease should ask a cardiologist whether sexual activity is safe for them before even considering a PDE5 inhibitor
  • Never combine a PDE5 inhibitor with nitrates or nitric oxide donor drugs — this is the one absolute contraindication in this drug class
  • Tell your doctor about every medication you take, especially alpha-blockers and other blood pressure-lowering drugs
  • PDE5 inhibitors don't substitute for hormonal diagnostics — if low libido is also present, it's worth considering a testosterone level check
  • "Potency supplements" bought outside the regulated pharmacy chain have repeatedly been found adulterated with undeclared sildenafil at an unknown dose — a real interaction risk for anyone on cardiac medication without knowing it

Sildenafil or tadalafil — a practical comparison

FeatureSildenafil (Viagra)Tadalafil (Cialis)
Onset of actionAbout 30–60 minutesAbout 30–45 minutes (on-demand dose)
Duration of action4–6 hoursUp to 36 hours
Effect of foodA fatty meal significantly delays absorptionMuch less affected by food
Dosing scheduleOn demand, before activityOn demand or once daily at a low dose
Typical side effectsHeadache, facial flushing, dyspepsiaSimilar, back and muscle pain reported more often

Sildenafil versus tadalafil at a glance

Choosing between the two drugs is rarely a matter of pure efficacy — in head-to-head trials, differences in patient satisfaction are small, and the decision more often comes down to whether someone values spontaneity (tadalafil) or a shorter, predictable window of action (sildenafil), along with the side-effect profile and coexisting conditions assessed by the prescribing doctor.

Our editorial recommendation

Few drug classes carry as solid a multi-decade body of evidence as PDE5 inhibitors — from pivotal trials a quarter-century old to pooled analyses of thousands of patients. That doesn't change the fact that these are prescription drugs with one absolute contraindication and a rare but serious ophthalmologic risk that's easy to overlook when treating them like an over-the-counter supplement. Their value is real — provided proper diagnosis comes first and the interactions, which in this specific case can literally be a matter of life and death, are respected.

The efficacy of sildenafil and tadalafil is among the best documented in all of urology — but it's precisely that well-established status that becomes dangerous when it leads people to dismiss the one absolute contraindication: nitrates.

Dr. Piotr Zieliński, VitMode editorial team

Frequently asked questions

In trials, each shows a significant advantage over placebo — in sildenafil's pivotal trial, 69% of attempts succeeded versus 22% on placebo, and in the tadalafil pooled analysis, 44.5% of patients with severe dysfunction reached a significant improvement threshold at the 5 mg dose versus 11.6% on placebo. Head-to-head comparisons show similar patient satisfaction between the two — the real difference lies mainly in duration of action and dosing convenience, not raw effect size.

Alcohol in larger amounts itself makes it harder to achieve an erection and can worsen blood pressure drops and dizziness associated with PDE5 inhibitors. Moderate consumption usually isn't an absolute contraindication, but it doesn't improve the drug's effectiveness, and with excess, it can actually blunt the therapeutic effect.

A lack of response to a PDE5 inhibitor can signal that the cause of erectile dysfunction lies outside the vascular mechanism these drugs target — for example low testosterone, severe nerve damage after pelvic surgery, a strong psychogenic component, or dosing mistakes (taking sildenafil after a fatty meal, or lacking real sexual stimulation). In such cases it's worth returning to a doctor for further evaluation rather than increasing the dose on your own.

There's no evidence of physiological dependence or of declining effectiveness with regular, correct use over time — unlike some psychoactive drugs, PDE5 inhibitors don't produce pharmacological tolerance in that sense.

It's worth first considering whether the episode is situational (stress, fatigue, alcohol, a new partner) or recurring and independent of context. Sudden, persistent erectile dysfunction in a younger man also warrants basic diagnostic workup, not just symptomatic treatment — sometimes it's an early sign of a hormonal or metabolic problem.

Sildenafil is approved in women only for a completely different indication — pulmonary arterial hypertension — at a different dose and formulation. It is not an approved treatment for female sexual dysfunction and shouldn't be used for that purpose without explicit medical indication.

Many such products, sold outside the regulated pharmacy supply chain, have in the past been found to contain undeclared sildenafil or similar substances at an unknown, sometimes very high dose — particularly dangerous for people taking nitrates who have no idea they're also taking a PDE5 inhibitor. A prescription drug of known composition and dose, obtained through a medical consultation, is the safer option.

Sources

PZ

dr Piotr Zieliński

Specialist physician in endocrinology, scientific consultant

Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.

Related articles

Dłonie pary splecione na białej pościeli

Premature Ejaculation: Causes and Evidence-Based Treatment

Premature ejaculation is one of the most common — and least reported to doctors — sexual conditions in men; epidemiological estimates suggest it affects as many as one in three to four men at some point in life. Despite how common it is, plenty of misconceptions surround its treatment: from the belief that it's purely a matter of "willpower," to overlooking the fact that the best-studied drugs for this condition are, in practice, antidepressants working through a completely different mechanism than in depression. We check what the research on causes and treatment efficacy actually shows.

13 min

September 4, 2026

Lekarz notujący szczegóły podczas konsultacji pacjenta w gabinecie

TRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy

Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.

7 min

July 29, 2026

Bogaty wybór świeżych składników na stole — różnorodność zdrowych opcji żywieniowych

Keto, DASH, or Mediterranean? Which Approach Has the Strongest Evidence for Weight Loss

We compare three popular eating patterns based on real scientific evidence — not social media popularity — to help you choose the approach that fits your goal.

8 min

July 31, 2026

Rzędy probówek z próbkami krwi w stojaku laboratoryjnym

5 Biomarkers Worth Knowing Before 40 — Signals Before Symptoms Appear

A standard "once-a-year blood count" often misses early signs of metabolic and hormonal issues. Here are five markers worth asking your doctor about, before anything starts to hurt.

7 min

August 1, 2026

Related knowledge base entries

Comments (2)

  • KW

    Kasia W. 2 weeks ago

    Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.

  • MT

    Marek T. a month ago

    Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.